{
  "schemaVersion": 1,
  "organisationId": "O-982ce3f5d25c4037b713f3ab1d096d3c",
  "slug": "vaxcyte-inc",
  "name": "Vaxcyte, Inc.",
  "updatedAt": "2026-10-02T15:53:43.883221Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial diseases. Its platform, XpressCF™, is designed to produce complex vaccine components. The company’s lead programs are pneumococcal conjugate vaccine candidates VAX-31 and VAX-24, alongside earlier-stage programs targeting Group A Streptococcus and Shigella. [P120331905][P147120934][P147120087]\n\nVaxcyte’s stated mission is to engineer “high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.” Headquartered in San Carlos, California, it also uses international manufacturing services, including a provider in Switzerland. As of June 30, 2026, it had no approved products and no product-sales revenue; its business remains focused on research and clinical development. [P120331905][P147120659][P147120872]\n[P120331905][P147120934][P147120087][P147120659][P147120872]",
      "updatedAt": "2026-10-02T15:53:43.883221Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Vaxcyte’s lead candidate, VAX-31, is an investigational 31-valent, carrier-sparing pneumococcal conjugate vaccine being developed for adults and infants. Its adult study evaluated single-injection doses of 1.1, 2.2 and 3.3 μg per serotype, with different dose levels for serotypes 1, 5 and 22F. The infant program evaluates a three-dose primary series at 2, 4 and 6 months followed by a booster at 12–15 months. The company estimates that VAX-31 could cover approximately 95% of U.S. adult and 92% of U.S. infant invasive pneumococcal disease. In 2026, adult Phase 3 trials and the infant Phase 2 study were fully enrolled. [P51384405][P7887075][P76304324][P77035533][P147120711]\n\nOther pneumococcal candidates include VAX-24, a 24-valent carrier-sparing vaccine targeting the 20 serotypes in PCV20 plus four additional serotypes, and VAX-XL, a preclinical third-generation candidate designed for broader serotype coverage; its specific valency and composition were not disclosed. VAX-A1 is a Group A Streptococcus vaccine candidate for diseases including pharyngitis and invasive infections; it entered an adult Phase 1 study in June 2026. VAX-GI is a preclinical Shigella vaccine candidate centered on the IpaB antigen; further development was paused in August 2025, with the option to resume retained. [P114244788][P72281865][P16328496][P88364646][P147120711][P57530333][P65498298]\n\nVaxcyte describes its platform as cell-free protein synthesis combined with proprietary carrier technology: non-native amino acids are introduced at selected sites in protein carriers to anchor polysaccharide antigens for site-specific conjugation. The company disclosed no services business or approved products, and reported no product-sale revenue for FY2025; product contribution percentages therefore were not reported. [P147120900][P102509185][P105198162]\n[P51384405][P7887075][P76304324][P77035533][P147120711][P114244788][P72281865][P16328496][P88364646][P57530333][P65498298][P147120900][P102509185][P105198162]",
      "updatedAt": "2026-10-02T15:53:43.883221Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Vaxcyte’s headquarters are in San Carlos, California, and the company reports that substantially all of its operations are conducted in the San Francisco Bay Area. The 2026 Q2 filing does not provide employee distribution by location or identify other company-operated offices. A dedicated manufacturing suite at Lonza’s facilities in Visp, Switzerland, was transferred to Lonza for operation on August 1, 2026.\n\nThe filing does not report revenue by geographic region. It describes Vaxcyte as a clinical-stage company and does not provide a consolidated country breakdown of its clinical trials; records for two VAX-24 studies list U.S. locations.\n[T16832192][P147120415][P147121112][P147120452][https://clinicaltrials.gov/study/NCT05266456][https://clinicaltrials.gov/study/NCT05297578]",
      "updatedAt": "2026-10-02T15:53:43.883221Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Vaxcyte, Inc. reports one operating and reportable segment. Its chief operating decision maker reviews financial information on a consolidated basis and allocates resources and evaluates performance using consolidated net loss. [P147120576]\n\nThe company also groups its pipeline into PCV programs (VAX-31, VAX-24 and VAX-XL) and non-PCV programs (VAX-A1, VAX-GI and discovery-stage programs), but these are program categories, not separately reported business segments. Vaxcyte does not allocate internal personnel costs by program and does not track external costs by individual candidate or project. [P147120711]\n\nNo percentage contribution by segment or program is reported. The 2026 second-quarter financial statements present results on a consolidated basis and report no revenue line. [T16832198]\n[P147120576][P147120711][T16832198]",
      "updatedAt": "2026-10-02T15:53:43.883221Z"
    },
    {
      "type": "HISTORY",
      "text": "Vaxcyte was founded in Delaware in 2013 as SutroVax, a spinout of Sutro Biopharma. Its founders were Grant Pickering, Jeff Fairman and Ash Khanna; in 2015, the company announced a $22 million Series A financing. [P98340591][https://www.sutrobio.com/sutrovax-raises-22-million-in-series-a/]\n\nIn May 2020, SutroVax changed its name to Vaxcyte, Inc., and in June it completed an initial public offering that raised approximately $264 million in net proceeds. [P98340591][https://vaxcyte.com/wp-content/uploads/2020/05/Vaxcyte-Name-Change-Press-Release_FINAL-20200520.pdf][https://investors.vaxcyte.com/static-files/c96b61ed-273f-4dc5-9946-5e50cbb29dd6]\n\nThe company advanced its pneumococcal vaccine candidate VAX-24 into clinical testing in 2022; the FDA granted it Breakthrough Therapy designation in January 2023. Vaxcyte began clinical testing of its next-generation candidate VAX-31 in late 2023 and reported positive Phase 1/2 topline results in 2024, selecting the high dose for adult Phase 3 development. [P37697305][P65721529][https://investors.vaxcyte.com/news-releases/news-release-details/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation][P102384735][P51908444]\n\nVAX-31 moved into pivotal Phase 3 development in 2025. In 2026, Vaxcyte reported that enrollment had been completed in two adult Phase 3 studies of the candidate. [P51908444][P89063288]\n[P98340591][https://www.sutrobio.com/sutrovax-raises-22-million-in-series-a/][https://vaxcyte.com/wp-content/uploads/2020/05/Vaxcyte-Name-Change-Press-Release_FINAL-20200520.pdf][https://investors.vaxcyte.com/static-files/c96b61ed-273f-4dc5-9946-5e50cbb29dd6][P37697305][P65721529][https://investors.vaxcyte.com/news-releases/news-release-details/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation][P102384735][P51908444][P89063288][https://www.sutrobio.com/sutrovax-raises-22-million-in-series-a/][https://vaxcyte.com/wp-content/uploads/2020/05/Vaxcyte-Name-Change-Press-Release_FINAL-20200520.pdf][https://investors.vaxcyte.com/static-files/c96b61ed-273f-4dc5-9946-5e50cbb29dd6][https://investors.vaxcyte.com/news-releases/news-release-details/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation]",
      "updatedAt": "2026-10-02T15:53:43.883221Z"
    }
  ],
  "sources": [
    {
      "id": "P120331905",
      "href": "https://app.finbar.com/go?id=P120331905",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P147120934",
      "href": "https://app.finbar.com/go?id=P147120934",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P147120087",
      "href": "https://app.finbar.com/go?id=P147120087",
      "label": "Vaxcyte, Inc. — Press release (2026 Q 2)",
      "documentId": "D-14a4dd4011ef43529280d4068b48392f"
    },
    {
      "id": "P147120659",
      "href": "https://app.finbar.com/go?id=P147120659",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P147120872",
      "href": "https://app.finbar.com/go?id=P147120872",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P51384405",
      "href": "https://app.finbar.com/go?id=P51384405",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P7887075",
      "href": "https://app.finbar.com/go?id=P7887075",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P76304324",
      "href": "https://app.finbar.com/go?id=P76304324",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P77035533",
      "href": "https://app.finbar.com/go?id=P77035533",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P147120711",
      "href": "https://app.finbar.com/go?id=P147120711",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P114244788",
      "href": "https://app.finbar.com/go?id=P114244788",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P72281865",
      "href": "https://app.finbar.com/go?id=P72281865",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P16328496",
      "href": "https://app.finbar.com/go?id=P16328496",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P88364646",
      "href": "https://app.finbar.com/go?id=P88364646",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P57530333",
      "href": "https://app.finbar.com/go?id=P57530333",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P65498298",
      "href": "https://app.finbar.com/go?id=P65498298",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P147120900",
      "href": "https://app.finbar.com/go?id=P147120900",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P102509185",
      "href": "https://app.finbar.com/go?id=P102509185",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P105198162",
      "href": "https://app.finbar.com/go?id=P105198162",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "T16832192",
      "href": "https://app.finbar.com/go?id=T16832192",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P147120415",
      "href": "https://app.finbar.com/go?id=P147120415",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P147121112",
      "href": "https://app.finbar.com/go?id=P147121112",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P147120452",
      "href": "https://app.finbar.com/go?id=P147120452",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "https://clinicaltrials.gov/study/NCT05266456",
      "href": "https://clinicaltrials.gov/study/NCT05266456",
      "label": "clinicaltrials.gov"
    },
    {
      "id": "https://clinicaltrials.gov/study/NCT05297578",
      "href": "https://clinicaltrials.gov/study/NCT05297578",
      "label": "clinicaltrials.gov"
    },
    {
      "id": "P147120576",
      "href": "https://app.finbar.com/go?id=P147120576",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "T16832198",
      "href": "https://app.finbar.com/go?id=T16832198",
      "label": "Vaxcyte, Inc. — Full financial report (2026 Q 2)",
      "documentId": "D-d6dc8df3c0b448bd817a29d95f4e0414"
    },
    {
      "id": "P98340591",
      "href": "https://app.finbar.com/go?id=P98340591",
      "label": "Vaxcyte, Inc. — Full financial report (2021 Y)",
      "documentId": "D-027cad44aa1440cb8153787226fc78e2"
    },
    {
      "id": "https://www.sutrobio.com/sutrovax-raises-22-million-in-series-a/",
      "href": "https://www.sutrobio.com/sutrovax-raises-22-million-in-series-a/",
      "label": "www.sutrobio.com"
    },
    {
      "id": "https://vaxcyte.com/wp-content/uploads/2020/05/Vaxcyte-Name-Change-Press-Release_FINAL-20200520.pdf",
      "href": "https://vaxcyte.com/wp-content/uploads/2020/05/Vaxcyte-Name-Change-Press-Release_FINAL-20200520.pdf",
      "label": "vaxcyte.com"
    },
    {
      "id": "https://investors.vaxcyte.com/static-files/c96b61ed-273f-4dc5-9946-5e50cbb29dd6",
      "href": "https://investors.vaxcyte.com/static-files/c96b61ed-273f-4dc5-9946-5e50cbb29dd6",
      "label": "investors.vaxcyte.com"
    },
    {
      "id": "P37697305",
      "href": "https://app.finbar.com/go?id=P37697305",
      "label": "Vaxcyte, Inc. — Full financial report (2021 Y)",
      "documentId": "D-027cad44aa1440cb8153787226fc78e2"
    },
    {
      "id": "P65721529",
      "href": "https://app.finbar.com/go?id=P65721529",
      "label": "Vaxcyte, Inc. — Full financial report (2021 Y)",
      "documentId": "D-027cad44aa1440cb8153787226fc78e2"
    },
    {
      "id": "https://investors.vaxcyte.com/news-releases/news-release-details/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation",
      "href": "https://investors.vaxcyte.com/news-releases/news-release-details/vaxcytes-vax-24-granted-fda-breakthrough-therapy-designation",
      "label": "investors.vaxcyte.com"
    },
    {
      "id": "P102384735",
      "href": "https://app.finbar.com/go?id=P102384735",
      "label": "Vaxcyte, Inc. — Full financial report (2023 Y)",
      "documentId": "D-68d7469757a548a782bbd7ea883408e5"
    },
    {
      "id": "P51908444",
      "href": "https://app.finbar.com/go?id=P51908444",
      "label": "Vaxcyte, Inc. — Full financial report (2025 Y)",
      "documentId": "D-7324ee6c5031490e9646943486a8b9dc"
    },
    {
      "id": "P89063288",
      "href": "https://app.finbar.com/go?id=P89063288",
      "label": "Vaxcyte, Inc. — Press release (2026 Q 1)",
      "documentId": "D-aaeb0d625f6c475f9a16868c72fb5bce"
    }
  ]
}